Table II.

Analytical data relative to proliferation suppression assays performed with CD8+CD28 or CD8+CD28+ T cells from primitive tumor lesions or satellite lymph nodesa

Patient No.Neg. Contr.Anti-CD3 PBMCAnti-CD3 PBMC + tumCD8+CD28Anti-CD3 PBMC + tumCD8+CD28 + Anti-IL-10Anti-CD3 PBMC + tumCD8+CD28 + ControlAnti-CD3 PBMC + CD8+CD28+Anti-CD3 PBMC + mLNCD8+CD28Anti-CD3 PBMC + mLNCD8+CD28 + Anti-IL-10Anti-CD3 PBMC + mLNCD8+CD28 + ControlAnti-CD3 PBMC + m-fLNCD8+CD28Anti-CD3 PBMC + m-fLNCD8+CD28 + Anti-IL-10Anti-CD3 PBMC + m-fLNCD8+CD28 + Control
1445 ± 163,935 ± 882,660 ± 1263,872 ± 952,713 ± 193
2647 ± 113,525 ± 2502,603 ± 1883,417 ± 2232,658 ± 84
3413 ± 162,794 ± 111,536 ± 732,682 ± 4431,582 ± 282,867 ± 521,117 ± 2872,458 ± 721,086 ± 138
4338 ± 192,820 ± 3151,833 ± 212,540 ± 351,857 ± 73
5394 ± 793,030 ± 662,771 ± 1153,062 ± 682,795 ± 63
6487 ± 443,127 ± 1422,095 ± 1092,939 ± 1382,174 ± 362,126 ± 1362,845 ± 572,087 ± 59
7397 ± 142,811 ± 532,092 ± 1812,670 ± 452,086 ± 812,750 ± 1171,394 ± 632,698 ± 2711,421 ± 49
8339 ± 122,757 ± 942,596 ± 1362,596 ± 2582,536 ± 138
9499 ± 122,879 ± 191,669 ± 822,504 ± 731,627 ± 1462,447 ± 152,810 ± 422,413 ± 36
10431 ± 262,927 ± 562,048 ± 192,751 ± 3821,986 ± 452,815 ± 641,990 ± 362,868 ± 1461,937 ± 271
11416 ± 233,672 ± 402,166 ± 903,561 ± 722,141 ± 843,608 ± 952,533 ± 593,561 ± 842,599 ± 853,414 ± 573,681 ± 353,461 ± 74
12663 ± 184,021 ± 4432,211 ± 553,860 ± 162,291 ± 1123,914 ± 721,608 ± 4413,538 ± 481,648 ± 311
13441 ± 132,776 ± 761,880 ± 982,581 ± 671,884 ± 622,482 ± 1822,692 ± 1722,450 ± 107
14546 ± 302,935 ± 1191,730 ± 322,641 ± 151,648 ± 362,902 ± 81
15419 ± 133,029 ± 271,938 ± 562,514 ± 1071,875 ± 62
16715 ± 182,789 ± 771,995 ± 192,621 ± 2321,958 ± 522,652 ± 332,080 ± 1812,510 ± 1122,136 ± 168
17315 ± 735,183 ± 91,669 ± 2124,457 ± 1381,672 ± 134
18157 ± 523,996 ± 2621,020 ± 243,396 ± 160995 ± 474,027 ± 2311,399 ± 2603,516 ± 3571,428 ± 215
19517 ± 333,774 ± 3712,490 ± 843,472 ± 3572,581 ± 632,830 ± 153,472 ± 1083,338 ± 95
20321 ± 234,237 ± 2342,230 ± 3513,855 ± 672,221 ± 1714,239 ± 79
21416 ± 233,672 ± 401,354 ± 3203,611 ± 521,312 ± 951,580 ± 403,310 ± 561,647 ± 723,198 ± 1173,649 ± 1143,236 ± 85
22544 ± 236,023 ± 144,336 ± 1565,240 ± 1014,217 ± 1285,541 ± 1684,517 ± 254,999 ± 1094,461 ± 206
23818 ± 738,028 ± 2127,385 ± 767,867 ± 447,391 ± 59
24903 ± 117,314 ± 1322,767 ± 2406,082 ± 2182,745 ± 281
25756 ± 235,874 ± 332,349 ± 675,286 ± 762,296 ± 895,767 ± 1812,760 ± 785,169 ± 122,791 ± 161
26464 ± 236,670 ± 354,135 ± 446,469 ± 934,108 ± 596,725 ± 494,402 ± 236,136 ± 1244,378 ± 1896,269 ± 876,469 ± 3916,301 ± 57
27387 ± 743,878 ± 662,326 ± 1823,645 ± 322,215 ± 68
28512 ± 444,136 ± 972,274 ± 1563,639 ± 682,145 ± 1174,114 ± 52
29250 ± 6774,818 ± 7325,985 ± 44333,668 ± 1116,193 ± 18472,588 ± 257
30252 ± 3885,443 ± 32711,107 ± 5977,753 ± 13313,858 ± 13683,912 ± 96
31258 ± 1216,820 ± 874,977 ± 8310,428 ± 344,961 ± 57
32516 ± 1813,190 ± 3818,837 ± 3912,002 ± 2918,894 ± 7813,861 ± 1439,101 ± 1612,266 ± 779,262 ± 284
42332 ± 2122,456 ± 3765,614 ± 8921,468 ± 3835,829 ± 11323,165 ± 315
  • a Neg. contr., irradiated macrophages plus nonstimulated PBMC; anti-CD3 PBMC, irradiated macrophages plus anti-CD3 mAb-stimulated PBMC; anti-CD3 PBMC + tum-CD8+CD28, as anti-CD3 PBMC plus CD8+CD28 T cells purified from primitive tumor lesion; anti-CD3 PBMC + CD8+CD28 + anti-IL-10, as anti-CD3 PBMC + CD8+CD28 plus an anti-IL-10 mAb (10 μg/ml); anti-CD3 PBMC + CD8+CD28 + control, as anti-CD3 PBMC + CD8+CD28 plus an unrelated, isotype-matched mAb (10 μg/ml); anti-CD3 PBMC + CD8+CD28+, as anti-CD3 PBMC plus CD8+CD28+ T cells purified from primitive tumor lesion; anti-CD3 PBMC + mLN-CD8+CD28, as anti-CD3 PBMC plus CD8+CD28 T cells purified from a metastatic lymph node; anti-CD3 PBMC + mLNCD8+CD28 + anti-IL-10: as anti-CD3 PBMC + mLNCD8+CD28 plus an anti-IL-10 mAb (10 μg/ml); anti-CD3 PBMC + mLNCD8+CD28 + control, as anti-CD3 PBMC + mLNCD8+CD28 plus an unrelated, isotype-matched mAb (10 mg/ml); anti-CD3 PBMC + m-fLN-CD8+CD28, as anti-CD3 PBMC plus CD8+CD28 T cells purified from a metastasis-free satellite lymph node; anti-CD3 PBMC + m-fLN-CD8+CD28 + anti-IL-10, as anti-CD3 PBMC + m-fLN-CD8+CD28 plus an anti-IL-10 mAb (10 μg/ml); anti-CD3 PBMC + m-fLN-CD8+CD28 + control, as anti-CD3 PBMC + m-fLN-CD8+CD28 plus an unrelated, isotype-matched mAb (10 μg/ml). Data are expressed as cpm ± SD.